{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:26Z","timestamp":1784822606167,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA","award":["CrossRef Funder ID: 10.13039\/100004755"],"award-info":[{"award-number":["CrossRef Funder ID: 10.13039\/100004755"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00968-2","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:57:21Z","timestamp":1781899041000},"page":"2041-2057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World, Long-Term Outcomes with Cladribine Tablets Versus Other Oral Treatments Among Patients with Multiple Sclerosis"],"prefix":"10.1007","volume":"15","author":[{"given":"Ajay S.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna P.","family":"MacEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"8","key":"968_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765\u201379. https:\/\/doi.org\/10.1001\/jama.2020.26858.","journal-title":"JAMA"},{"key":"968_CR2","unstructured":"National Multiple Sclerosis Society. What is multiple sclerosis. 2025. https:\/\/www.nationalmssociety.org\/understanding-ms\/what-is-ms. Accessed Sept 11, 2025."},{"issue":"10","key":"968_CR3","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States a population-based estimate using health claims data. Neurology. 2019;92(10):e1029\u201340. https:\/\/doi.org\/10.1212\/WNL.0000000000007035.","journal-title":"Neurology"},{"issue":"15","key":"968_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.90.15_supplement.P1.140","volume":"90","author":"K Sharma","year":"2018","unstructured":"Sharma K, Bittner F, Kamholz J. Epidemiology of multiple sclerosis in the United States (P1.140). Neurology. 2018;90(15):P1.140. https:\/\/doi.org\/10.1212\/WNL.90.15_supplement.P1.140.","journal-title":"Neurology"},{"issue":"7","key":"968_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","volume":"80","author":"M Hittle","year":"2023","unstructured":"Hittle M, Culpepper WJ, Langer-Gould A, et al. Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region. JAMA Neurol. 2023;80(7):693\u2013701. https:\/\/doi.org\/10.1001\/jamaneurol.2023.1135.","journal-title":"JAMA Neurol"},{"key":"968_CR6","unstructured":"National Institute of Neurological Disorders and Stroke. National Institute of Health. Multiple sclerosis. https:\/\/www.ninds.nih.gov\/healthinformation\/disorders\/multiple-sclerosis. Accessed Sept 17, 2025."},{"issue":"1","key":"968_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2807-x","volume":"17","author":"A Sicras-Mainar","year":"2017","unstructured":"Sicras-Mainar A, Ru\u00edz-Beato E, Navarro-Artieda R, Maurino J. Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Serv Res. 2017;17(1):854. https:\/\/doi.org\/10.1186\/s12913-017-2807-x.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"968_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159129","volume":"11","author":"O Ernstsson","year":"2016","unstructured":"Ernstsson O, Gyllensten H, Alexanderson K, Tingh\u00f6g P, Friberg E, Norlund A. Cost of illness of multiple sclerosis\u2014a systematic review. PLoS ONE. 2016;11(7):e0159129. https:\/\/doi.org\/10.1371\/journal.pone.0159129.","journal-title":"PLoS ONE"},{"issue":"12","key":"968_CR9","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.18553\/jmcp.2023.23039","volume":"29","author":"M Schauf","year":"2023","unstructured":"Schauf M, Chinthapatla H, Dimri S, Li E, Hartung DM. Economic burden of multiple sclerosis in the United States: a systematic literature review. J Manag Care Spec Pharm. 2023;29(12):1354\u201368. https:\/\/doi.org\/10.18553\/jmcp.2023.23039.","journal-title":"J Manag Care Spec Pharm"},{"issue":"18","key":"968_CR10","doi-asserted-by":"publisher","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","volume":"98","author":"B Bebo","year":"2022","unstructured":"Bebo B, Cintina I, LaRocca N, et al. The economic burden of multiple sclerosis in the United States estimate of direct and indirect costs. Neurology. 2022;98(18):e1810\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000200150.","journal-title":"Neurology"},{"key":"968_CR11","unstructured":"National Multiple Sclerosis Society. Disease modifying therapies. https:\/\/www.nationalmssociety.org\/managing-ms\/treating-ms\/disease-modifying-therapies. Accessed Sept 19, 2025."},{"issue":"17","key":"968_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):789\u2013800. https:\/\/doi.org\/10.1212\/WNL.0000000000005345.","journal-title":"Neurology"},{"key":"968_CR13","unstructured":"Ford CC. Update on disease-modifying therapy for relapsing and progressive forms of MS. In: CMSC, editors. Best practices in multiple sclerosis therapies 2025 update. https:\/\/www.mscare.org\/best-practices-in-multiple-sclerosis-therapies\/. Accessed Sept 19, 2025."},{"issue":"2","key":"968_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049.","journal-title":"Mult Scler"},{"key":"968_CR15","unstructured":"US Food and Drug Administration. Mavenclad\u00ae highlights of prescribing information. 2024. https:\/\/www.emdserono.com\/us-en\/pi\/mavenclad-pi.pdf. Accessed June 6, 2025."},{"issue":"5","key":"968_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326. https:\/\/doi.org\/10.1056\/NEJMoa0902533.","journal-title":"N Engl J Med"},{"issue":"12","key":"968_CR17","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/13524585177276","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594\u2013604. https:\/\/doi.org\/10.1177\/13524585177276.","journal-title":"Mult Scler"},{"issue":"6","key":"968_CR18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1177\/13524585231161494","volume":"29","author":"G Giovannoni","year":"2023","unstructured":"Giovannoni G, Boyko A, Correale J, et al. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: an ambispective study. Mult Scler. 2023;29(6):719\u201330. https:\/\/doi.org\/10.1177\/13524585231161494.","journal-title":"Mult Scler"},{"issue":"3","key":"968_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/1352458520921087","volume":"27","author":"N Lizak","year":"2021","unstructured":"Lizak N, Hodgkinson S, Butler E, et al. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy. Mult Scler. 2021;27(3):465\u201374. https:\/\/doi.org\/10.1177\/1352458520921087.","journal-title":"Mult Scler"},{"issue":"2","key":"968_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1352458522113750","volume":"29","author":"T Spelman","year":"2023","unstructured":"Spelman T, Ozakbas S, Alroughani R, et al. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry. Mult Scler. 2023;29(2):221\u201335. https:\/\/doi.org\/10.1177\/1352458522113750.","journal-title":"Mult Scler"},{"key":"968_CR21","unstructured":"Gupta A, MacEwan J. P, Anderson J, et al. Comparative assessment of treatment switching for cladribine tablets versus fingolimod, dimethyl fumarate, and teriflunomide in patients with multiple sclerosis at 4\u00a0years. In: Presented at: the consortium of multiple sclerosis centers 2025 annual meeting; 28\u201331 May\u00a02025; Phoenix, AZ, USA. DMT43."},{"key":"968_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106272","volume":"94","author":"DS Conway","year":"2025","unstructured":"Conway DS, Nicholas JA, Thompson NR, Mowry EM, Naismith RT. Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers. Mult Scler Relat Disord. 2025;94:106272. https:\/\/doi.org\/10.1016\/j.msard.2025.106272.","journal-title":"Mult Scler Relat Disord"},{"key":"968_CR23","unstructured":"Lobo C, Chen X, Zhao X, et al. Comparative assessment of switching outcomes for patients with multiple sclerosis receiving cladribine tablets vs fingolimod, dimethyl fumarate, and teriflunomide. In: Poster presented at ninth annual Americas committee for treatment and research in multiple sclerosis (ACTRIMS) Forum 2024; February 29\u2013March 2, 2024; West Palm Beach, FL, USA. P488."},{"key":"968_CR24","unstructured":"Healthcare Map\u2122. https:\/\/www.komodohealth.com\/solutions\/healthcare-map\/. Accessed Aug 2, 2025."},{"issue":"3","key":"968_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.03.528","volume":"16","author":"X Song","year":"2013","unstructured":"Song X, Capkun-Niggli G, Johnson BH, Kahler K. Medical and pharmacy claims-based algorithims for identifying patients with multiple sclerosis. Value Health. 2013;16(3):A111. https:\/\/doi.org\/10.1016\/j.jval.2013.03.528.","journal-title":"Value Health"},{"issue":"5","key":"968_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1185\/03007995.2015.1014029","volume":"31","author":"G Capkun","year":"2015","unstructured":"Capkun G, Lahoz R, Verdun E, et al. Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis. Curr Med Res Opin. 2015;31(5):1029\u201339. https:\/\/doi.org\/10.1185\/03007995.2015.1014029.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"968_CR27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.msard.2015.08.005","volume":"4","author":"G Capkun","year":"2015","unstructured":"Capkun G, Dahlke F, Lahoz R, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord. 2015;4(6):546\u201354. https:\/\/doi.org\/10.1016\/j.msard.2015.08.005.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"968_CR28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3111\/13696998.2010.523670","volume":"13","author":"BJ Chastek","year":"2010","unstructured":"Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618\u201325. https:\/\/doi.org\/10.3111\/13696998.2010.523670.","journal-title":"J Med Econ"},{"issue":"5","key":"968_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"issue":"6","key":"968_CR30","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139. https:\/\/doi.org\/10.1016\/0895-4356(92)90133-8.","journal-title":"J Clin Epidemiol"},{"key":"968_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102741","volume":"49","author":"JC Toliver","year":"2021","unstructured":"Toliver JC, Barner JC, Lawson KA, Rascati KL. Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population. Mult Scler Relat Disord. 2021;49:102741. https:\/\/doi.org\/10.1016\/j.msard.2021.102741.","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"968_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.18553\/jmcp.2002.8.6.469","volume":"8","author":"DA Ollendorf","year":"2002","unstructured":"Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8(6):469\u201376. https:\/\/doi.org\/10.18553\/jmcp.2002.8.6.469.","journal-title":"J Manag Care Pharm"},{"key":"968_CR33","unstructured":"Komodo Health: imputing allowed amounts: development and validation of an encounter-level allowed amount imputation model. 2023. https:\/\/www.komodohealth.com\/hubfs\/2023\/Komodo_Imputing_Allowed_Amounts_White_Paper.pdf?hsLang=en. Accessed Sept 13, 2025."},{"issue":"1","key":"968_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observation studies for causal effects. Biometrika. 1983;70(1):41\u201355. https:\/\/doi.org\/10.1093\/biomet\/70.1.41.","journal-title":"Biometrika"},{"key":"968_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1626317","volume":"16","author":"A Pogoda-Weso\u0142owska","year":"2025","unstructured":"Pogoda-Weso\u0142owska A, St\u0119pie\u0144 A, Wnuk M, et al. Cladribine tablets as therapy for advanced relapsing-remitting multiple sclerosis: a 4-year follow-up real-world, multi-center, retrospective, cohort study. Front Neurol. 2025;16:1626317. https:\/\/doi.org\/10.3389\/fneur.2025.1626317.","journal-title":"Front Neurol"},{"key":"968_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105704","volume":"88","author":"MC Kowarik","year":"2024","unstructured":"Kowarik MC, Ernst M, Woitschach L, et al. Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year\u00a04\u2014results from a German cladribine cohort. Mult Scler Relat Disord. 2024;88:105704. https:\/\/doi.org\/10.1016\/j.msard.2024.105704.","journal-title":"Mult Scler Relat Disord"},{"key":"968_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106724","volume":"103","author":"I Rauma","year":"2025","unstructured":"Rauma I, Viitala M, Soilu-H\u00e4nninen M, et al. The real-world efficacy of cladribine tablets and treatment persistence in people with highly active relapsing multiple sclerosis in Finland\u2014a follow-up study after four years of observation. Mult Scler Relat Disord. 2025;103:106724. https:\/\/doi.org\/10.1016\/j.msard.2025.106724.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"968_CR38","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200415","volume":"12","author":"T Guerra","year":"2025","unstructured":"Guerra T, Copetti M, Zanetta C, et al. The Italian multiple sclerosis register experience with cladribine: impact on relapses, pira, and treatment sequencing strategies evaluation. Neurol Neuroimmunol Neuroinflamm. 2025;12(4):e200415. https:\/\/doi.org\/10.1212\/NXI.0000000000200415.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"968_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420922685","volume":"13","author":"F Patti","year":"2020","unstructured":"Patti F, Visconti A, Capacchione A, Roy S, Trojano M. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian Multiple Sclerosis Registry (CLARINET MS). Ther Adv Neurol Disord. 2020;13:1756286420922685. https:\/\/doi.org\/10.1177\/1756286420922685.","journal-title":"Ther Adv Neurol Disord"},{"key":"968_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251360047","volume":"18","author":"M Lucchini","year":"2025","unstructured":"Lucchini M, Borriello G, Haggiag S, et al. Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study. Ther Adv Neurol Disord. 2025;18:17562864251360047. https:\/\/doi.org\/10.1177\/17562864251360047.","journal-title":"Ther Adv Neurol Disord"},{"issue":"7","key":"968_CR41","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","volume":"270","author":"C Zanetta","year":"2023","unstructured":"Zanetta C, Rocca MA, Meani A, et al. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol. 2023;270(7):3553\u201364. https:\/\/doi.org\/10.1007\/s00415-023-11700-7.","journal-title":"J Neurol"},{"key":"968_CR42","unstructured":"Vermersch P, Wiendl H, Leocani L, et al. Long-term effect of cladribine tablets on disability progression and improvement: insights from pooled analyses of CLARIFY-MS and MAGNIFY-MS Studies. In: Poster presented at 41st congress of the European Committee for treatment and research in multiple sclerosis (ECTRIMS); 24\u201326 September 2025; Barcelona, Spain. P335."},{"issue":"2","key":"968_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.18553\/jmcp.2024.30.2.129","volume":"30","author":"P Racsa","year":"2024","unstructured":"Racsa P, Kiss C, Stevens L, Dixon SW, Ellis JJ. A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis. J Manag Care Spec Pharm. 2024;30(2):129\u201340. https:\/\/doi.org\/10.18553\/jmcp.2024.30.2.129.","journal-title":"J Manag Care Spec Pharm"},{"key":"968_CR44","doi-asserted-by":"publisher","unstructured":"Avila-Ornelas J, Abdalla K, Roman C, et al. Real-world treatment outcomes in people with multiple sclerosis switched from platform MS treatments to fumarates versus other oral disease-modifying therapies (P8\u20131.010). Neurology. 2025; 104(8):P8\u20131.010. https:\/\/doi.org\/10.1212\/WNL.00000000002084.","DOI":"10.1212\/WNL.00000000002084"},{"issue":"2","key":"968_CR45","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/neurolint16020029","volume":"16","author":"M Moccia","year":"2024","unstructured":"Moccia M, Affinito G, Marrazzo G, et al. Utilization of ocrelizumab within different treatment strategies for multiple sclerosis: a 5-year population-based study. Neurol Int. 2024;16(2):394\u2013405. https:\/\/doi.org\/10.3390\/neurolint16020029.","journal-title":"Neurol Int"},{"key":"968_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105380","volume":"82","author":"D Rog","year":"2024","unstructured":"Rog D, Brownlee W, Carod-Artal FJ, et al. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: a time and motion study. Mult Scler Relat Disord. 2024;82:105380. https:\/\/doi.org\/10.1016\/j.msard.2023.105380.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"968_CR47","doi-asserted-by":"publisher","DOI":"10.1177\/2055217318819031","volume":"4","author":"JD Bowen","year":"2018","unstructured":"Bowen JD, Kozma CM, Grosso MM, Phillips AL. A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs. Mult Scler J Exp Transl Clin. 2018;4(4):2055217318819031. https:\/\/doi.org\/10.1177\/2055217318819031.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"968_CR48","unstructured":"Schmierer K. Durable effects of cladribine tablets on CSF OCB and NfL over 4\u00a0years in relapsing multiple sclerosis: results from the MAGNIFY-MS extension study. In: Presented at: Americas Committee for treatment and research in multiple sclerosis (ACTRIMS) forum; Feb 27\u2013Mar 1 2025; West Palm Beach, FL, USA. P143."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00968-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00968-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00968-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:52Z","timestamp":1784819512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00968-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00968-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ajay Gupta has received compensation for consulting or speaking from EMD Serono, Inc., Boston, MA, USA, an affiliate of Merck KGaA. Joanna P. MacEwan, Jeffrey Anderson, Xin Zhao, Sonia Kim, and Yu Hong are employees of Genesis Research. Genesis Research received funding from EMD Serono, Inc., Boston, MA, USA, an affiliate of Merck KGaA. Andy Surinach was a former employee of Genesis Research during the manuscript development. He is currently affiliated with Argenx, Hoboken, NJ, USA. Jeffrey Anderson was a former employee of Genesis Research during the manuscript development. He is currently affiliated with ICA, Inc., Arlington, VA, USA. Amy Phillips and Xiaoxue Chen are employees of EMD Serono, Inc., Boston, MA, USA, an affiliate of Merck KGaA.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This non-interventional, retrospective study involved analysis of secondary, deidentified data. Therefore, independent ethics committee\/institutional review board approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}